Danish drug group Lundbeck has entered a research consortium with five other giants and leading research institutes to discover future treatments of mental illness. The consortium hopes to find at least 10 new projects and if two of these make it to the clinic, the collaboration is a success, says Lundbeck's project coordinator.
Especially one analyst remained skeptical towards Ambu’s praise for its growth hope, the colonoscope SC210. “It’s okay to be optimistic but you still have to give the market correct information,” says the Carnegie analyst who was not particularly surprised by Ambu’s recent adjustment of the financial outlook and following share price decline.
With the acquisition of Swedish Trimb, the chairman of Karo Pharma sets out to realize the goal of becoming Northern Europe's leading specialty pharma company.
Fertin Pharma's latest annual report reveals a declined revenue and operating profit, but CEO Søren Birn is ready with a growth plan that involves much more than nicotine chewing gum.
